Global Injectables Gland Pharma operates a global footprint across 60 countries with a strong focus on sterile injectables, oncology and ophthalmics. Potential sales opportunity: pursue international supply partnerships and contract manufacturing for complex injectable formulations with healthcare systems and large distributors in key regions.

CDMO Growth Recent data highlights rising CDMO revenue and a pipeline expansion with four new molecules launched in the US market. Potential sales opportunity: position as a strategic API and finished-dose CDMO partner for injectable pipeline development, scale-up capabilities, and regulatory support.

Leadership Change CEO transition occurred in 2026 with new leadership planned. Potential sales opportunity: engage during leadership onboarding to align strategic partnerships, emphasize continuity in supply quality, and propose collaboration on long-term manufacturing roadmaps.

Financial Momentum Revenue trajectory shown with year-over-year growth and a solid profit improvement in Q1 FY27 alongside notable CDMO revenue growth. Potential sales opportunity: present value-driven partnerships, cross-sell across finished formulations and API lines, and offer scalable manufacturing capacity to meet demand surges.

US Market Focus Active US market presence with recent US launches and a dedicated US turnover for Gland US. Potential sales opportunity: target US-based hospital networks, specialty distributors, and Medicare/Medicaid supply channels with compliant injectable products and reliable on-time delivery.